Detail akcie MPL-USA online

Business Summary: Molecular Pharmacology (USA) Limited (Molecular USA) is an Australia-based development Stage company together with its subsidiary, Molecular Pharmacology Pty. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The Company and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
Financial Summary: BRIEF: For the three months ended 30 September 2014, Molecular Pharmacology (USA) Limited revenues was not reported. Net loss decreased 29% to $29K. Lower net loss reflects Consulting decrease of 55% to $7K (expense), Professional fees decrease of 45% to $8K (expense), Amortization remaining flat at $0K.